Quarterly report pursuant to Section 13 or 15(d)

Other current assets (Details)

v3.19.3
Other current assets (Details) - USD ($)
$ in Thousands
Oct. 31, 2019
Sep. 30, 2019
Dec. 31, 2018
Corporate tax receivable   $ 30,341 $ 16,459
Prepayments   10,391 6,279
Clinical materials   1,522 1,087
VAT receivable   1,385 1,505
Other current assets   471 439
Total   $ 44,110 $ 25,769
Subsequent events      
Amount of corporate tax receivable attributable to research and expenditures $ 15,800